Aktis Oncology (AKTS) Stock Analysis: AI Score & Alternative Data
AKTS alt-data: job postings climbing, web traffic lagging
Is Aktis Oncology a buy right now? The alternative data says hold. This AKTS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Aktis Oncology every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 52/100: a Hold. The stock trades at $15.06 with a $890M market cap.
The bullish side of the 90-day ledger: job postings up 25.0% to 5 open roles, and headcount (according to LinkedIn) up 6.1% to 105 employees. The drag: web traffic down 41.9% to 5K monthly visits. That tension is what keeps the score mid-range.
AKTS’s broader alt-data profile also covers sentiment (100/100). Every signal links to its own page with full history, the AKTS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on AKTS is just below.
Aktis Oncology AI Stock Analysis
Aktis Oncology is a biopharmaceutical company specializing in the development and commercialization of novel cancer treatments. The company focuses on leveraging innovative technologies and collaborations to bring new oncology therapies to market.
Analysis generated October 3, 2026.
Recent Aktis Oncology Stock Alerts
|
Aktis Oncology | October 16 Price is down by -6.3% in the last 24h. |
|
Aktis Oncology | September 26 Insider Alert: Czibere Akos is selling shares |
|
Aktis Oncology | September 23 Price is down by -6.4% in the last 24h. |
|
Aktis Oncology | September 8 Price is down by -6.1% in the last 24h. |
Aktis Oncology Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 5K | 41.9% | |
| Job Posts | 5 | 25.0% | |
| LinkedIn Employees | 105 | 6.1% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 43 | 975.0% | |
| Stocktwits Mentions | 0 | 100.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 3K | 1.1% | |
| 4chan Mentions | 0 | N/A |
About Aktis Oncology (AKTS)
Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.
| Price | $15.06 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $890M |
| Year Range | $15 – $32 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Aktis Oncology News
View more →
Aktis Oncology to Present at the Jefferies Global Healthcare ConferenceMay 27 - GlobeNewswire |
|
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing TumorsMay 21 - GlobeNewswire |
|
Aktis Oncology to Present at the BofA Securities Health Care ConferenceMay 6 - GlobeNewswire |
|
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)May 4 - GlobeNewswire |
|
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingApril 21 - GlobeNewswire |
See Aktis Oncology’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for AKTS, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEAktis Oncology Earnings & Financial Performance
View all earnings →Aktis Oncology Insider Trading Activity
View all →| Czibere Akos filed to sell 7,401 shares at $0.0. Sep 23 '26 |
| Czibere Akos filed to sell 0 shares at $0.0. Sep 23 '26 |
| Herrmann Ken filed to sell 0 shares at $0.0. Jul 20 '26 |
| Herrmann Ken filed to sell 1,350 shares at $0.0. Jul 20 '26 |
| Herrmann Ken filed to sell 0 shares at $0.0. Jul 17 '26 |
Aktis Oncology Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Aktis Oncology
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Theravance BiopharmaTBPH |
$17.03 0.0% | $884M | 44 |
 |
MoonLake ImmunotherapeuticsMLTX |
$9.55 6.9% | $878M | 52 |
 |
Monte Rosa TherapeuticsGLUE |
$9.74 3.8% | $863M | 52 |
 |
VerastemVSTM |
$8.65 6.3% | $836M | 54 |
 |
MeiraGTx HldgsMGTX |
$9.28 6.2% | $950M | 41 |
Explore Aktis Oncology Data
Frequently Asked Questions: Aktis Oncology (AKTS)
Aktis Oncology has an AltIndex AI Score of 52/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
52/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Aktis Oncology (AKTS) stock is $15.06 with a market cap of $890M.
As of today, Aktis Oncology’s PE (Price to Earnings) ratio is —.
View the latest Aktis Oncology insider transactions to see recent buying and selling activity by company executives and directors.
Check the Aktis Oncology congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The AKTS stock price chart above shows Aktis Oncology’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Aktis Oncology technical analysis for RSI, moving averages, and more.
See the stocks similar to Aktis Oncology section on this page for companies in the same industry ranked by market cap and AI Score.
